PA HB2181

Amends the Controlled Substance, Drug, Device and Cosmetic Act to expand the definition of "opioid antagonist" to explicitly include nalmefene hydrochloride alongside naloxone hydrochloride

Opioid antagonists are defined as FDA-approved drugs or devices for emergency reversal of known or suspected opioid overdose

Includes any similarly acting drugs approved by the FDA for opioid overdose treatment

Takes effect 60 days after enactment